ConductScience.org, home

Paper32802408

Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.

Sahin I and 6 others. Cell Death Discov, 2020. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. Papers, record 32802408. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32802408

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.
PubMed
Journal
Cell Death Discov
PubMed
Year
2020
PubMed
Publication types
Published Erratum
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.25
iCite
Revised in PubMed
2023-09-26
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sahin IIlyas
2Zhang SShengliang
3Navaraj AArunasalam
4Zhou LLanlan
5Dizon DDon
6Safran HHoward
7El-Deiry WSWafik Shttps://orcid.org/0000-0002-9577-8266

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum for32655895AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.https://conductscience.org/library/papers/32655895

Source PubMed

Download CSV of comments and corrections

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
40211092
A working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era.
J Natl Cancer Inst2025https://conductscience.org/library/papers/40211092PubMed
39253578Protein ubiquitination in ovarian cancer immunotherapy: The progress and therapeutic strategy.Genes Dis2024https://conductscience.org/library/papers/39253578PubMed
38476371The role of immunotherapy sensitizers and novel immunotherapy modalities in the treatment of cancer.Front Oncol2024https://conductscience.org/library/papers/38476371PubMed
36899853RUNX3 Meets the Ubiquitin-Proteasome System in Cancer.Cells2023https://conductscience.org/library/papers/36899853PubMed
35765530AMG-232, a New Inhibitor of MDM-2, Enhance Doxorubicin Efficiency in Pre-B Acute Lymphoblastic Leukemia Cells.Rep Biochem Mol Biol2022https://conductscience.org/library/papers/35765530PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
MDM24193PubTator's text mininghttps://conductscience.org/library/genes/4193

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32802408

GET https://conductscience.org/api/papers/v1/32802408/authors